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New blood vessels are initially formed
through the assembly or sprouting of endo-
thelial cells, but the recruitment of support-
ing pericytes and vascular smooth muscle
cells (mural cells) ensures the formationof a
mature and stable vascular network. Defec-
tive mural-cell coverage is associated with
the poorly organized and leaky vasculature
seen in tumors or other human diseases.
Here we report that mural cells require eph-
rin-B2, a ligand for Eph receptor tyrosine
kinases, for normal association with small-
diameter blood vessels (microvessels). Tis-
sue-specific mutant mice display perinatal
lethality; vascular defects in skin, lung, gas-
trointestinal tract, andkidneyglomeruli; and
abnormal migration of smooth muscle cells
to lymphatic capillaries.Culturedephrin-B2-
deficient smooth muscle cells are defective
in spreading, focal-adhesion formation, and
polarized migration and show increased
motility. Our results indicate that the role
of ephrin-B2 and EphB receptors in these
processes involves Crk-p130(CAS) signal-
ing and suggest that ephrin-B2 has some
cell-cell-contact-independent functions.
INTRODUCTION
The coordinated generation of different cell types and their
organization into functional structures are key processesduring tissue morphogenesis. In the cardiovascular system,
endothelial cells (ECs) that form the inner lining of blood ves-
sels need to recruit different types of mural cells to form
stable and functional structures (Carmeliet, 2003; Gerhardt
et al., 2003; Jain, 2003). Pericytes (PCs), which share the
basal lamina with the endothelium, extend numerous cellular
processes that are in direct contact with ECs. This interac-
tion leads to a quiescent phenotype of the vasculature (i.e.,
the formation of new endothelial sprouts is suppressed)
and prevents leakage through the vessel wall by reducing
the permeability of the endothelial monolayer. Pericytes are
confined to newly formed vascular structures, capillaries, and
postcapillary venules. In contrast, larger blood vessels are
covered by vascular smoothmuscle cells (vSMCs), which at-
tach in one or multiple layers to the external (abluminal) side
of the endothelial basal lamina. vSMCs produce extracellular
matrix and elastic fibers that provide vessels with the neces-
sary structural stability and elasticity. Both mural-cell types
have been linked to human pathologies: The loss of pericyte
coverage in the retinae of diabetic patients leads to in-
creased vascular permeability, aberrant endothelial sprout-
ing, and, ultimately, blindness (Adamis et al., 1999; Betsholtz
et al., 2005). Lesions in the smooth muscle cell layer and ab-
normal vSMC migration can block blood flow through ar-
teries in atherosclerosis (Faxon et al., 2004). The molecular
mechanismsmediating endothelial-mural interactions are in-
completely understood, but previous work has highlighted
the importance of transforming growth factor b, sphingosine
1-phosphate, angiopoietin-1, platelet-derived growth factor
B (PDGF-B), and their respective receptors in this process
(Betsholtz et al., 2005; Jain, 2003).
Eph receptor tyrosine kinases (RTKs) and their cell-surface-
anchored ephrin ligands are versatile regulators of tissue
morphogenesis and blood-vessel formation. Ephrin-B2, a
transmembrane protein with a short cytoplasmic tail, is pre-
dominantly expressed on arterial ECs in several vertebrate
species, whereas one of its binding partners, the receptor
EphB4, is largely confined to veins (Adams et al., 1999;
Figure 1. Phenotype of PC/vSMC-Specific Efnb2 Mutants
(A–E) Expression of ephrin-B2 in arterial and venous mural cells. Immunofluorescence on sections of E17.5 wild-type mesenteric artery (a) and vein (v) with
antibodies recognizing EphB4 (A) or ephrin-B2 (B) (green) and a-smooth muscle actin (a-SMA, red). Ephrin-B2 protein is present on arterial ECs and, at
lower level, on arterial and venous mural cells. Similar patterns were seen in the mesentery of Efnb2-lacZ (Wang et al., 1998) heterozygous embryos by
anti-b-galactosidase immunofluorescence (green, [C]) or b-galactosidase staining ([D] and arrow in [E]). No specific signal was seen in venous ECs (arrow-
head in [E]).
(F–I) Hemorrhaging in the skin of a freshly isolated E18.5 (embryonic day 18.5) Efnb2DPC/vSMC (Efnb2) embryo (G). A littermate control is shown in (F). Arrows
in (H) and (I) are pointing at hemorrhagic lesions in mutant face and forelimb.
(J and K) Immunofluorescence on sections of control and mutant skin arteries with primary antibodies directed against ephrin-B2 (green) and a-SMA (red).
Red and green signals overlap only in vSMCs of controls (J), whereas ECs remain positive (arrows).
(L and M) Freshly isolated intestines. Mutants show hemorrhaging and accumulation of blood in mesenteric lymphatics.
(N–S) Hematoxylin and eosin (H&E) stained tissue sections from mutant and control E18.5 embryos as indicated.162 Cell 124, 161–173, January 13, 2006 ª2006 Elsevier Inc.
Gerety et al., 1999;Wanget al., 1998). Gene targeting experi-
ments in mice have demonstrated that ephrin-B2 (encoded
by the gene Efnb2) and EphB4 (Ephb4) are equally essential
for the angiogenic remodeling of blood vessels in the early
embryo, which suggests that theymediate vascular morpho-
genesis through reciprocal interactions and bidirectional sig-
naling (Adams et al., 1999; Gerety et al., 1999; Wang et al.,
1998). The lethality of these global knockouts seems to indi-
cate an essential function in the endothelium because EC-
specific inactivation ofEfnb2 is also incompatible with embry-
onic angiogenesis and survival beyond midgestation (Gerety
and Anderson, 2002). However, ephrin-B2 is also expressed
in a range of other cell types and tissues such as PCs and
vSMCs (Gale et al., 2001; Shin et al., 2001), but the early le-
thality of the existing mutant mousemodels has so far limited
functional studies in vivo. Therefore, we have employed a
conditional gene targeting (Cre-loxP) approach to selectively
disrupt expression of the ligand in pericytes and vSMCs.
RESULTS
Mural-Cell-Specific Inactivation of Efnb2
In the developing vascular system, ephrin-B2 is expressed in
the arterial endothelium, where its expression is highest, as
well as in the mural cells covering arteries and veins (Figures
1A–1E). To study the role of the Eph RTK ligand in pericytes
and vSMCs, transgenic Pdgfrb-Cremice (S.S.F. and R.H.A.,
unpublished data), which express Cre recombinase under
the control of a fragment of the gene encoding platelet-
derived growth factor receptor PDGFRb, were bred into a
background of mice carrying a loxP-flanked version of the
Efnb2 gene (Efnb2lox/lox) (Grunwald et al., 2004). This ap-
proach directs Efnb2 inactivation to mural cells in many or-
gans, including skin, intestine, kidney, lung, and the vascular
plexus surrounding the central nervous system (see Fig-
ure S1 in the Supplemental Data available with this article on-
line). The resulting Efnb2DPC/vSMC mutants develop to term
but die shortly after birth due to respiratory failure (data not
shown). Freshly isolated embryos at embryonic day 18.5
(E18.5) display edema and extensive hemorrhaging in the
skin (Figures 1F–1I). The absence of ephrin-B2 protein in
Efnb2DPC/vSMC smooth muscle cells was confirmed by im-
munofluorescence on tissue sections (Figures 1J and 1K).
Furthermore, genotyping of freshly isolated endothelial
cells verified the integrity of the loxP-flanked gene fragment
in isolated endothelial cells from Efnb2DPC/vSMC heterozy-
gotes (Figure S1). EphB4 protein equally marks veins in
Efnb2DPC/vSMC and control tissues, indicating that mutant
blood vessels adopt normal arterial-venous identities (data
not shown).
In addition to the defects in mutant skin described above,
mural-cell-specific loss of ephrin-B2 affects a range of or-gans. Freshly isolated intestines are pale and mesenteric
lymphatics are filled with red blood cells, indicating hemor-
rhage (Figures 1L and 1M). Sectioning of intestinal walls re-
vealed the presence of large blood-filled spaces (Figures
1N and 1O). In mutant kidneys, comma- and S-shaped bod-
ies develop normally, but the more mature glomerular tufts,
formed by capillaries and mesangial cells, are poorly orga-
nized (Figures 1P and 1Q). Hemorrhaging in the lungs of
Efnb2DPC/vSMC embryos provides a possible explanation for
the respiratory arrest observed at birth (Figures 1R and 1S).
Loss of Ephrin-B2 Disrupts Microvessel Architecture
The characterization of Pdgfb and Pdgfrb knockout mice
has established that insufficient proliferation and recruitment
of PCs/vSMCs leads to compromised integrity of blood ves-
sels in skin andmesentery, disorganization of kidney glomer-
uli, and perinatal lethality similar to what we observed for
Efnb2DPC/vSMC mutants (Hellstrom et al., 1999; Lindahl
et al., 1998; Soriano, 1994). However, we found that the
number of vSMCs and PCs covering the Efnb2DPC/vSMC mu-
tant vasculature is comparable to control tissues (Figure S2).
Since mural-cell numbers fail to provide an explanation for
the defects in the Efnb2DPC/vSMC vasculature, we examined
the spatial organization of pericytes and vSMCs associated
with microvessels at high resolution. We found that smooth
muscle cells are scattered, resulting in an incomplete cover-
age of microvessels (Figures 2A and 2B). The presence of
rounded vSMCs suggests that these cells require ephrin-
B2 for proper spreading and attachment (Figures 2C and
2D). Similarly, pericytes, which normally wrap tightly around
capillaries, show diminished interaction with microvessels in
Efnb2DPC/vSMC embryos. Frequently, mutant PCs bridge two
capillaries, make only loose contact with ECs, stretch away
from vessels, or appear rounded (Figures 2E–2I). On the ul-
trastructural level, Efnb2DPC/vSMC pericytes associate poorly
with capillaries, and abnormal deposits of extracellular matrix
can be seen in gaps separating PCs from the endothelium
(Figures 2L–2O). Mutant vessels are frequently ruptured and
release blood cells into the surrounding tissue (Figure 2P).
Furthermore, excessive deposits of collagen fibers are found
in the proximity of mutant mural cells (Figure 2Q).
Ephrin-B2 Is Required for Directional Migration
and Cell-Matrix Interactions
To study the molecular nature of the Efnb2DPC/vSMC pheno-
type, we established an aortic smooth muscle cell line from
mice carrying two copies of the loxP-flanked Efnb2 allele
(see Experimental Procedures). These cells show robust lev-
els of ephrin-B2 protein as well as expression of the recep-
tors EphB2, EphB3, and EphB4 (Figure 3A). All the cells in
our cultures are capable of binding soluble ephrin-B2 or
EphB4 fusion proteins, indicating coexpression of ligand(N and O) Large blood-filled lacunae are visible in mutant intestine (arrowhead in [O]).
(P and Q) Poor organization and dilation of glomerular tufts in mutant kidney (arrow in [Q]).
(R and S) Hemorrhaging in mutant lungs (arrows in [S]).
Magnifications are 630 in (A)–(D), (J), and (K); 1000 in (E); 8 in (F) and (G); 20 in (H) and (I); 10 in (L) and (M); 200 in (N), (O), (R), and (S); and 400 in
(P) and (Q).Cell 124, 161–173, January 13, 2006 ª2006 Elsevier Inc. 163
Figure 2. Defective Microvessel Archi-
tecture in Efnb2 Mutants
(A–D) Whole-mount preparations showing the
endothelial network (anti-PECAM-1, red) and as-
sociated vSMCs (a-SMA, green) in control (ctrl)
and mutant (Efnb2) skin at E18.5. Continuous
vSMC coating of microvessels in control skin (A
and C) but patchy coverage and poor association
of mutant cells (B and D) are seen. Note rounded
shape of mutant cells (arrowheads in [D]).
(E andF) Anti-desmin staining labeling pericytes in
skin sections. Pericyte processes envelope con-
trol capillaries (E), whereas mutant pericytes fre-
quently bridge two capillaries (F).
(G–K) Whole-mount skin labeling of endothelial
cells (anti-PECAM-1, red) and associated peri-
cytes (anti-desmin, green). Pericytes are tightly
integrated into vessel walls of E18.5 control em-
bryos (G and J). Note loose attachment (arrow-
heads in [H]) and rounded appearance of peri-
cytes (arrowhead in [K]) in Efnb2DPC/vSMC skin. (I)
shows a higher magnification of the inset in (H).
Note gap between desmin-stained PC and the
endothelium.
(L–Q) Electron micrographs from E18.5 skin sec-
tions.
(L–O) Endothelial-pericyte contacts are extensive
in control capillaries (L and N), whereas mutant
pericytes are only loosely associated (M and O).
Matrix-filled gaps separate endothelial cells (ec)
and pericytes (pc) in Efnb2DPC/vSMC mutants (ar-
row in [M]).
(P) Rupturing of mutant microvessels leading to
hemorrhage (arrow).
(Q) Excessive deposition of collagen fibers in the
dermal tissue surrounding mutant blood vessels
(arrows).
Magnification is 400 in (A), (B), and (E)–(K) and
630 in (C), (D), and (I). Scale bar in (Q) corre-
sponds to 2 mm in (L) and (M), 1.5 mm in (N) and
(O), 10 mm in (P), and 1 mm in (Q).and receptors (data not shown). Next, we generated ephrin-
B2-deficient (Dephrin-B2) and control cells by transfecting
cultured vSMCs with a Cre expression construct or empty
vector, respectively (see Experimental Procedures). As ex-
pected, the loxP-flanked Efnb2 gene section is deleted (Fig-
ure S3) andephrin-B2protein expression isabsent inDephrin-
B2 cells (Figure 3B). Tyrosine-phosphorylated EphB4 recep-
tor is readily detectable in control SMCs, whereas activation
of the receptor is absent in cells lacking ephrin-B2. However,
stimulation of Dephrin-B2 cells with soluble recombinant
ephrin-B2 fusion proteins leads to robust binding and
EphB4 phosphorylation (Figure 3C and Figure S3).
Lossof ephrin-B2 leads to strikingmorphological changes:
(1) The cells are elongated and insufficiently spread, (2) they
show numerous lamellipodial protrusions in a nonpolarized
fashion, and (3) cell detachment at the rear end is compro-164 Cell 124, 161–173, January 13, 2006 ª2006 Elsevier Inc.mised (Figures 3D and 3E). Live video microscopy (see
Experimental Procedures) revealed that Dephrin-B2 lamelli-
podia are highly instable and tend to collapse after short
phases of rapid extension. New lamellipodia are constantly
formed in other parts of the cells, resulting in frequent
changes of direction, random but accelerated movement,
and poor spreading (Figure S4; Movies S1 and S2). Surpris-
ingly,Dephrin-B2 cells show this behavior in low-density cul-
tures in a cell-cell-contact-independent (autonomous) fash-
ion. In scratch assays (i.e., the wounding of confluent cell
layers), ephrin-B2-deficient vSMCs migrate faster but more
randomly than control cells (data not shown). After the closing
of the scratch wounds, control vSMCs display reduced mo-
tility, whereas Dephrin-B2 cells continue to migrate actively,
indicating that cell-cell-contact-dependent interactions
through ephrin-B2 inhibit cell migration (Movies S3 and S4).
Figure 3. Generation and Characteriza-
tion of Ephrin-B2-Deficient vSMCs
(A) Western blots showing expression of ephrin-
B2 in immortalized aortic SMCs and E12.5mouse
embryos (control) but not in human umbilical vein
ECs (HUVEC). Immunoprecipitation shows ex-
pression of EphB receptors in SMCs (right panel).
Antibodies and molecular-weight marker are indi-
cated.
(B) Absence of ephrin-B2 protein expression in
Dephrin-B2 (D) cells was confirmed by WGA
pull-down and Western blotting. PDGFRb levels
are equal in Dephrin-B2 and control (c) vSMCs.
(C) Immunoprecipitated EphB4 is phosphorylated
on tyrosine (4G10 antibody staining) in control but
not Dephrin-B2 mock-treated (IgG Fc fragment)
vSMCs. Treatment with soluble recombinant
ephrin-B2/Fc fusion (B2/Fc) induces EphB4 acti-
vation in Dephrin-B2 and, to a small extent, con-
trol cells.
(D and E) Confocal interference reflection mi-
croscopy showing the abnormal morphology of
Dephrin-B2 cells. Arrows in (E) indicate numerous
cellular protrusions, and the arrowhead points at
the long tail at the rear end. Front and rear end
are labeled in (D).
(F–K) Focal-adhesion organization in control or
ephrin-B2-deficient cells (as indicated) as seen by
immunofluorescence with antibodies recognizing
paxillin (F, G, J, and K) or integrin a5 (H and I).
Note reduced number of inner FAs (F and G)
and lack of FA formation in the lamellipodia of
Dephrin-B2 vSMCs (H and I). Arrows in (H) point
at new FAs in a control lamellipodium. Peripheral
focal adhesions are enlarged and disorganized in
the absence of ephrin-B2 (J and K).
(L and M) Still images from interference reflection
microscopy videos showing formation of new FAs
(arrow and arrowhead in [L]) in control but not
Dephrin-B2 lamellipodia (M). The two images for
each cell type are separated by 5min. SeeMovies
S5 and S6 for videos.
(N and O) Double immunofluorescence show-
ing FA formation in lamellipodia of control and
Dephrin-B2 cells (see labeling for cell types and
antibodies). The number of newly formed FAs is
small in Dephrin-B2 protrusions. Insets show ex-
amples of maturing FAs, which display low FAK
activation in the absence of ephrin-B2.
(P–S) P-FAK and phospho-p130(CAS) (P-CAS,
antibody recognizing tyrosine residue 165) over-
lap with integrin a5 at peripheral focal adhesions.
(T–V) Rescue of cell spreading and FA organiza-
tion defects in Dephrin-B2 cells by re-expression
of YFP-tagged ephrin-B2 (U) or an activated
(C1199) and GFP-tagged form of Tiam1 (V).
Magnifications are 630 in (D)–(G), (L), (M), and
(T)–(V) and 1000 in (H)–(K) and (N)–(S).Cell 124, 161–173, January 13, 2006 ª2006 Elsevier Inc. 165
Figure 4. Modulation of Focal-Adhesion Formation through EphB-Ephrin-B2 Signaling
(A) Still images from a confocal reflection microscopy video showing reorganization of FAs in control cells stimulated with ephrin-B2/Fc (time points as in-
dicated). Cell movement is reduced (but cells continue to ruffle actively and form new protrusions). FAs in the center (arrowheads) are weakened, whereas
peripheral FAs (arrows) are strengthened. See Movie S7 for video.
(B) Increased association of p130(CAS) (CAS) with Crk immunoprecipitated from Dephrin-B2 cells compared to control. Total CAS levels are not altered in
the absence of ephrin-B2. Tyrosine phosphorylation (4G10) of Crk-associated CAS is reduced in Dephrin-B2 vSMCs. Quantification of Crk-CAS coimmu-
noprecipitation (n = 4) and CAS phosphorylation experiments (n = 3) are shown on the right (control = 100%). Standard deviations and statistical significance
by t test (*p < 0.03; **p = 0.01) are indicated.
(C) Western blots showing phosphorylation levels of CrkII (after immunoprecipitation of total Crk) and CrkL (in lysate by P-CrkL antibody) 30 min after stim-
ulation with IgG Fc, EphB4/Fc, or ephrin-B2/Fc.
(D and E) Active Src (P-Src, red) overlaps with internalized ephrin-B2/Fc (green) and, to a lesser extent, EphB4/Fc in the perinuclear region of stimulated
vSMCs (arrows).
(F) P-Src (red) and ephrin-B2/Fc signals overlap in Dephrin-B2 cells (arrow).166 Cell 124, 161–173, January 13, 2006 ª2006 Elsevier Inc.
The abnormal morphology andmotility ofDephrin-B2 cells
does not obviously correlate with cytoskeletal defects, as tu-
bulin microfilaments, actin stress fibers in the cell body, and
the F-actin network at the leading edge of lamellipodia can
be formed (Figure S2). In contrast, cell-matrix contacts, vis-
ible as focal adhesions (FAs), are dramatically altered in the
absence of ephrin-B2. Control vSMCs exhibit numerous fo-
cal adhesions in both the periphery and the center, whereas
central FAs are reduced in Dephrin-B2 cells (Figures 3F and
3G). Likewise, FAs and more immature focal contacts are
abundant in control lamellipodial protrusions but are sparse
or missing in the absence of ephrin-B2 (Figures 3H and 3I).
Dephrin-B2 peripheral focal adhesions appear enlarged and
irregular (Figures 3J and 3K). Similar defects were seen in
cells cultured on fibronectin, collagen, or laminin substrates
(Figure S3).
To observe dynamic changes affecting FA formation and
turnover, we studied migrating cells using live confocal inter-
ference reflectionmicroscopy (IRM; see Experimental Proce-
dures). This method showed that control cells constantly
form new FAs behind their leading edge and progress
steadily across these cell-matrix contacts. In contrast, very
few or no FAs form within Dephrin-B2 lamellipodia (Figures
3L and 3M; Movies S5 and S6). Focal adhesions are large
protein complexes assembled around activated integrin re-
ceptors (Mitra et al., 2005; Wehrle-Haller and Imhof, 2002).
In the lamellipodia of control vSMCs, integrin a5, which forms
functional integrin heterodimers with the b1 subunit, over-
laps with other FA components in numerous structures of
different size. Such sites of integrin-mediated cell-matrix ad-
hesion are rare in Dephrin-B2 cells (Figures 3N and 3O).
Moreover, focal complexes, small and immature cell-matrix
interaction sites, show reduced activation of focal adhesion
kinase (FAK), indicating that Dephrin-B2 cells may be defec-
tive in thematuration of FAs at themigration front (Figures 3N
and 3O). In this context, it is noteworthy that processes
occurring within the Dephrin-B2 leading edge appear un-
affected, i.e., FAK, paxillin, and other FA proteins are pres-
ent as in control cells (Figures 3N and 3O and data not
shown).
Despite the abnormal shape ofDephrin-B2 peripheral FAs,
integrins are capable of signaling in response to matrix en-
gagement in these structures: FAK is activated, vinculin and
paxillin are recruited, and the adaptor molecules CrkL/CrkII
and p130(CAS) are present (Figures 3P–3S and data not
shown).
The defects described above can be rescued by re-
expressing ephrin-B2 (Figures 3T and 3U). Similarly, expres-
sion of an activated version of Tiam1 (T-lymphoma invasion
and metastasis), an activator for the Rho-like GTPaseRac1, restores spreading and (to some extent) FA formation
in Dephrin-B2 cells (Figure 3V).
Role of Ephrin-B2 in Focal-Adhesion Formation
and Motility
To address the question of how ephrin-B2 can control FA
formation and motility, we monitored vSMCs after stimula-
tion with soluble recombinant ephrin-B2/Fc or EphB4/Fc fu-
sion proteins by live IRM (see Experimental Procedures).
Prior to stimulation, control vSMCs move in a steady fashion
involving the constant formation of new FAs behind the lead-
ing edge. Internal FAs are also readily visible in the reflection
images (Movie S7). Within minutes after activation of endog-
enous EphB receptors with ephrin-B2/Fc, cells stopmoving,
although the peripheral membrane continues to ruffle. Focal
adhesions reorganize significantly in the following hour, as
internal FAs are reduced (or eliminated) whereas peripheral
FAs are strengthened in areas of both cell expansion and re-
traction (Figure 4A; Movie S7). Cell migration is also reduced
after treatment with EphB4 or ephrin-B2 fusion proteins in
transwell assays (Figure S5).
What are the signaling processes that might link ephrin-B2
and its receptors, which themselves show no obvious FA lo-
calization (Figures 5G, 5L, and 5N), to focal-adhesion orga-
nization and motility? The Crk-family proteins CrkII and CrkL,
cytoplasmic adapters composed of Src homology SH2 and
SH3 domains, are important regulators of cell migration and
FA formation. Complexes between Crk proteins and Crk-
associated substrate p130(CAS) interconnect integrin and
growth factor receptor signaling by promoting local Rac
GTPase activation, actin dynamics, and the formation of la-
mellipodial protrusions (Chodniewicz and Klemke, 2004).
The activity of Crk-p130(CAS) complexes is tightly regulated
by tyrosine kinases and phosphatases: Phosphorylation of
Crk blocks its association with p130(CAS) but also promotes
translocation of the protein within the cell. In turn, a series of
tyrosine residues within p130(CAS) require phosphorylation
by kinases (such as FAK or Src) for Crk binding. Several pro-
tein tyrosine phosphatases (PTPs) also control Crk and
p130(CAS) activity through dephosphorylation of these pro-
teins (Chodniewicz and Klemke, 2004). Since previous work
has linked Eph-ephrin signaling andCrk-mediated regulation
of cell adhesion and membrane ruffling (Lawrenson et al.,
2002; Nagashima et al., 2002; Sakamoto et al., 2004),
we checked whether loss of ephrin-B2 leads to alterations
in this pathway. Indeed, Crk-p130(CAS) association is in-
creased in Dephrin-B2 SMCs, consistent with the enhanced
motility of these cells (Figure 4B). At the same time, tyrosine
phosphorylation of Crk-associated p130(CAS) is reduced,
suggesting that the complex of these proteins might be(G) Distribution of phospho-CrkL (P-CrkL) in control orDephrin-B2 cells stimulated with IgG Fc, EphB4/Fc, or ephrin-B2/Fc as indicated. Note accumulation
of signal in clusters inside ephrin-B2/Fc-treated control cells (red arrows).
(H) Merged images of P-CrkL stainings (as shown in [G], red) and bound Fc fusion proteins detected by anti-Fc antibody (green). Note the overlap of the two
signals in ephrin-B2/Fc-treated control cells (yellow spots).
(I) Higher magnification of insets in (H) showing internalized Fc proteins (green) and P-CrkL staining (red). Note the extensive overlap of P-CrkL and ephrin-
B2/Fc signals in control but not Dephrin-B2 cells. Images of the P-CrkL channel are shown in Figure S4.
Magnifications are 630 in (A), (G), and (H) and 1000 in (D)–(F) and (I).Cell 124, 161–173, January 13, 2006 ª2006 Elsevier Inc. 167
Figure 5. Effect of EphB/Ephrin-B2
Depletion on Cell Motility
(A–C) Still images from video microscopy show-
ing control cells 4, 5, and 6 hr after stimulation
with IgG Fc (A), ephrin-B2/Fc (B), or EphB4/Fc
(C). Green and red arrows indicate the extension
or retraction of cellular protrusions, respectively.
See Movies S8–S10 for videos.
(D–I) Anti-ephrin-B2 immunofluorescence of
vSMCs at the indicated times after stimulation
with IgG Fc (D–F) or EphB4/Fc (G–I).
(J) Absence of specific ephrin-B2 staining in
Dephrin-B2 cells treated with EphB4/Fc.
(K) Absence of binding of Alexa 488-coupled
EphB4/Fc to Dephrin-B2 4 hr after stimulation
with unlabeled IgG.
(L and M) Detection of ephrin-B2 by binding of
Alexa 488-coupled EphB4/Fc 4 hr after stimula-
tion with unlabeled IgG Fc (L) or EphB4/Fc (M).
(N and O) Detection of EphB receptors by binding
of Alexa 488-coupled ephrin-B2/Fc 4 hr after
stimulation with unlabeled IgG Fc (N) or ephrin-
B2/Fc (O).
Magnifications are 400 in all panels.less stable than in control cells (Figure 4B). As Src, one of the
kinases involved in p130(CAS) phosphorylation, is activated
downstream of EphB/ephrin-B molecules (Figures 4D–4F;
Palmer et al., 2002; Zisch et al., 1998), it is possible that
the lack of ephrin-B2 compromises this pathway. However,
other explanations, such as increased PTP activity, appear
equally feasible.
Alterations in Dephrin-B2 cells may also directly involve
Crk-family proteins. siRNA-mediated reduction of Crk pro-
tein levels significantly decreases the migration speed of
Dephrin-B2 SMCs, indicating that Crk is rate limiting for the
motility of these cells (Figure S5 and Movies S11–S14). Re-168 Cell 124, 161–173, January 13, 2006 ª2006 Elsevier Inc.duced motility of SMCs after stimulation with ephrin-B2/Fc
or EphB4/Fc is accompanied by changes in the distribution
patterns of phospho-CrkL (P-CrkL) and phospho-CrkII (Fig-
ure 4G, Figure S5, and data not shown). Antibody signals
increase at peripheral FAs, hinting at phosphorylation/
dephosphorylation or protein translocation events. Clusters
of internalized ephrin-B2/Fc, but not EphB4/Fc, show exten-
sive overlap with phosphorylated CrkL and CrkII (Figures 4H
and 4I and data not shown). This may be caused by Crk
translocation because biochemical analysis of stimulated
cells provides no evidence for changes in total P-Crk levels
(Figure 4C). Moreover, Dephrin-B2 cells, in which P-CrkL/
CrkII signals are almost exclusively located to peripheral FAs,
show very little overlap with ephrin-B2/Fc after stimulation
(Figures 4H and 4I).
Not only does treatment of control vSMCs with ephrin-B2/
Fc or EphB4/Fc lead to relatively rapid changes in the FA pat-
tern, but hours after stimulation, the cells also display in-
creasingly altered motility. Most notably, these SMCs are
poorly spread and abnormally shaped, and movements fail
to translate into directional migration. New lamellipodia
are formed in quick succession but tend to be short lived
(Figures 5A–5C; Movies S8–S10). As this behavior mimics
Dephrin-B2 cells, we studied the fate of endogenous
ephrin-B2 protein in the hours following stimulation with
EphB4/Fc. Between 0.5 and 2.5 hr, the ligand is succes-
sively internalized and accumulated in the perinuclear region.
At 6.5 hr posttreatment, ephrin-B2 has been degraded al-
most entirely so that the remaining signal is comparable to
the unspecific background seen in Dephrin-B2 cells (Figures
5D–5K). Moreover, ephrin-B2/Fc or EphB4/Fc binding is ab-
sent 4 hr after cells have been prestimulated with the same
fusion protein (Figure 5L–5O), whereas binding capacity is
retained after 4 hr when cells were only transiently stimulated
for 1 hr (data not shown). Thus, the stimulation of vSMCs
with ephrin-B2/Fc or EphB4/Fc leads to a transient period
of signaling that is followed by a longer phase of protein deg-
radation/depletion. The latter phenocopies aspects of the
loss-of-function situation seen in Dephrin-B2 cells.
Mural-Cell Attachment and Motility In Vivo
Reminiscent of the motility and adhesion defects in cultured
Dephrin-B2 vSMCs, mural cells in Efnb2DPC/vSMC mutant
mice fail to attach properly to the blood-vessel endothelium
and are frequently scattered around microvascular beds
(Figures 2A and 2B and Figures 6A and 6B). We also ob-
served that Efnb2DPC/vSMC vSMCs cover large-diameter
PECAM-1-positive vessels in the skin, which were identified
as part of the lymphatic vasculature by staining with anti-
LYVE1 antibodies (Figures 6C–6G). These distal lymphatics
are essential for the removal of excess interstitial fluid and
extravasated molecules from the skin and are normally not
covered by smooth muscle (Oliver and Detmar, 2002; Pep-
per and Skobe, 2003; Saharinen and Petrova, 2004). Closer
examination showed that some Efnb2DPC/vSMC a-SMA-
positive cells are bridging blood vessels and lymphatics in
mutants, indicative of cells moving from one type of vessel
to another (Figure 6H).
Recent work has established that ectopic expression of
PDGF-B by lymphatic vessels in mice lacking the forkhead
transcription factor FoxC2 leads to abnormal recruitment
of mural cells (Petrova et al., 2004). We found that distal
lymphatics in the skin of mice lacking PDGFRb also carry
a-SMA-positive cells, although the overall numbers of mural
cells is dramatically reduced (Figures 6I and 6J). This sug-
gests that the ability to sense the chemotactic signal
PDGF-B (provided by the blood-vessel endothelium) pre-
vents aberrant migration of mural cells. Similarly, increased
but random motility might allow ephrin-B2-deficient vSMCsto leave blood vessels and occupy lymphatic capillaries (Fig-
ures 6E–6H).
DISCUSSION
Vascular morphogenesis involves the generation of endo-
thelial andmural cells, their migration to the proper locations,
Figure 6. Scattering of vSMCs and Ectopic Coverage of Lym-
phatics in Efnb2DPC/vSMC Mutants
(A and B) Whole-mount immunofluorescence showing the endothelial
network (PECAM-1, red) and vSMCs (a-SMA, green) in control and
Efnb2DPC/vSMC skin at E18.5. Loss of ephrin-B2 leads to scattering of
vSMCs (arrowheads in [B]).
(C and D) Ectopic vSMC coverage (a-SMA, green) on PECAM-1-stained
(red) large-diameter vessels (lymphatics) in mutant skin.
(E–G) Mutant a-SMA-positive cells (green, arrows) covering distal lym-
phatics (LYVE-1, blue) are visible in skin whole-mount preparations (E)
and sections (F and G). Blood vessels (b) and lymphatics (ly) are indicated.
(H) a-SMA-positive cells (green) are bridging blood vessels (outlined by
dotted lines) and lymphatics in Efnb2DPC/vSMC skin (PECAM-1, red).
(I and J) Immunofluorescence on Pdgfrb knockout (E18.5) skin whole-
mount (I) and section (J) with antibodies against LYVE-1 (blue) and
a-SMA (green). Arrows in (J) point at a-SMA-positive cells.
Magnifications are 100 in (A) and (B) and 400 in (C)–(J).Cell 124, 161–173, January 13, 2006 ª2006 Elsevier Inc. 169
Figure 7. Regulation of Vessel-Wall Assembly, Cell Motility, and Adhesion by Ephrin-B2
(A) Model showing possible sites of EphB-ephrin-B2 interactions between endothelial cells and pericytes (in microvessels, black arrows) as well as between
adjacent mural cells (in both small- and large-caliber vessels, red arrows). Ephrin-B2might control directional migration of PCs and the stabilization of mural-
cell coating on maturing blood vessels.
(B) EphB-ephrin-B2 interactions between adjacent cells lead to reduced cell motility and the reorganization of focal adhesions. A cell-autonomous function
of ephrin-B2 (possibly through interactions with coexpressed EphB RTKs) is required for new FA formation at the front end of migrating cells, directional
migration, and spreading. Our data indicate an involvement of the Crk-p130(CAS) signaling complex in these processes.and, finally, their assembly into functional structures. Here
we show that ephrin-B2, a cell-surface-anchored ligand for
Eph RTKs, is a critical regulator of mural-cell migration,
spreading, and adhesion during blood-vessel-wall assembly.
Surprisingly, the defects displayed by ephrin-B2-deficient
cells indicate that the ligand has cell-autonomous and cell-
cell-contact-dependent functions, both of which may be re-
quired for normal tissue morphogenesis.
Blood-Vessel-Wall Assembly
The Efnb2DPC/vSMC phenotype is best summarized as the in-
ability of mural cells to get functionally incorporated into the
wall of blood vessels: Ephrin-B2-deficient pericytes make in-
sufficient contacts with ECs, fail to envelope the endothelial
monolayer, and remain only loosely attached.Mutant vSMCs
appear poorly attached, cover small-diameter blood vessels
in a discontinuous fashion, and ectopically occupy lymphatic
capillaries in the skin. Although it is unclear whether all these
abnormally distributed cells are exclusively vSMCs—previ-
ous work has shown that detaching pericytes express
a-SMA (Morikawa et al., 2002)—defects in Efnb2DPC/vSMC
mice are not confined to any one of the two mural-cell sub-170 Cell 124, 161–173, January 13, 2006 ª2006 Elsevier Inc.classes. This is significant because pericytes and vSMCs as-
sociate with blood vessels in fundamentally different ways:
PCs make direct contact with ECs, whereas vSMCs are as-
sociated with the abluminal side of the basement mem-
brane. We propose that ephrin-B2 controls interactions be-
tween mural cells as well as between pericytes and the
endothelium (Figure 7A). These interactions may reduce
the migration of PCs/vSMCs and ensure that they cover ma-
turing vascular beds adequately and stably. Expression pat-
terns of the relevant players in vivo are consistent with such
a role: RT-PCR on freshly isolated Pdgfrb-Cre-positive mural
cells confirms the expression of several EphB receptors
(Figure S6). Efnb2-lacZ reporter expression is comparably
low and heterogeneous in microvascular beds but increases
with vessel diameter and can bemost robustly seen on larger
arteries. EphB2, detected with an Ephb2-lacZ knockin
reporter (Henkemeyer et al., 1996), is also present in the mu-
ral cells coating larger vessels (mainly arteries) in a range of
tissues (Figure S6). Immunohistochemistry data indicate
that mural cells similarly express the receptor EphB3 in a hi-
erarchical fashion (data not shown). Thus, mural ephrin-B2
and EphB RTK expression correlates with blood-vessel
maturation, and the phenotype of Efnb2mutants may reflect
a role in this process.
Another aspect of the Efnb2DPC/vSMC phenotype is that it
almost exclusively affects the architecture of microvessels,
whereas large-caliber blood vessels show onlyminor defects
(data not shown). This may reflect the higher sensitivity of the
more recently formed and therefore less mature microves-
sels and is similar to findings in Pdgfb mutants (Hellstrom
et al., 1999). Remarkably, Efnb2DPC/vSMC mice have other
features in common with mutants in the PDGF-B/PDGFRb
pathway: Malformations affect similar tissues (e.g., skin, kid-
ney, intestine), and the loose attachment of ephrin-B2-defi-
cient pericytes phenocopies defects in mutant mice ex-
pressing a truncated (and more diffusible) form of PDGF-B
(Lindblom et al., 2003). Misexpression of PDGF-B by lym-
phatic vessels leads to abnormal vSMC recruitment in mice
lacking the forkhead transcription factor FoxC2 and has
been linked to the human disease lymphedema distichiasis
(Petrova et al., 2004). Efnb2 and Pdgfrbmutants display ec-
topic vSMCcoverage on lymphatic capillaries, indicating that
both pathways provide important signals guiding mural cells
to the correct targets. Future work will seek to address
whether these signals act independently or in combination.
Role of Ephrin-B2 in Cell Spreading, Adhesion,
and Migration
Our analysis of cultured SMCs shows that ephrin-B2 con-
trols focal-adhesion formation, cell adhesion, spreading,
and directional migration (Figure 7B). What is the nature of
the link between Eph/ephrin molecules and these cellular
processes? Previous studies have proposed that Eph-ephrin
interactions modulate integrin-mediated adhesion and cell
migration through FAK or Src kinases, the adaptor mole-
cules Crk and p130(CAS), and Rho-family GTPases (Carter
et al., 2002; Deroanne et al., 2003; Huai and Drescher,
2001; Huynh-Do et al., 2002; Miao et al., 2005; Nagashima
et al., 2002; Sakamoto et al., 2004). Our own data point at
complexes of Crk adaptor proteins and p130(CAS), which
promote cell motility and spreading and the growth of lamel-
lipodial protrusions (Chodniewicz and Klemke, 2004). Crk-
p130(CAS) association is increased in Dephrin-B2 SMCs,
which is consistent with the increased motility and the rapid
extension of protrusions, whereas the phosphorylation of ty-
rosine residues in the stretch of 15 SH2 domain-docking
motifs of p130(CAS) is reduced. These two findings may ap-
pear contradictory at first glance—only phosphorylated CAS
can bind to Crk—but it is also known that a small subset of
the SH2 binding sites is sufficient for Crk association and mi-
gration of mouse embryonic fibroblasts (Shin et al., 2004).
Nevertheless, as the extent of p130(CAS) tyrosine phosphor-
ylation positively correlates with binding capacity (Shin et al.,
2004), the complex with Crk proteins might be less stable
and therefore more short lived in the absence of ephrin-
B2. Our results also indicate that the distribution and/or local
phosphorylation of Crk-family proteins may be regulated
through EphB/ephrin-B2 molecules. For example, stimu-
lated cells show phospho-CrkL/CrkII accumulation at clus-ters of internalized ephrin-B2/Fc (i.e., bound Eph receptors)
as well as at peripheral focal adhesions.
The sum of our results indicates that Crk-p130(CAS) sig-
naling is a key pathway downstream of EphB/ephrin-B2mol-
ecules (Figure 7B), which does not rule out some contribu-
tion of other molecular players.
Cell-Autonomous Function of Ephrin-B2
One of the most surprising findings in our studies, the abnor-
mal morphology and motility of Dephrin-B2 cells in the ab-
sence of cell-cell interactions, leads to the question of how
the ligand may function in a cell-autonomous mode. Is this
process based on receptor-independent signaling, or does
it involve interactionswith receptors in the same cell? Our ob-
servation that long-term stimulation of cells with EphB4/Fc
or ephrin-B2/Fc fusion protein leads to the depletion of the
corresponding binding partners (presumably through inter-
nalization and degradation of signaling complexes) provides
a clue that manipulation of EphB RTKs can lead to cell de-
fects similar to the loss/depletion of ephrin-B2. Conse-
quently, there may be some level of Eph-ephrin signaling
even in absence of contact with other cells. Such receptor-
ligand interactions in cis are supported by previous reports
showing that coexpression of EphA/ephrin-A molecules in
the same cell can lead to the masking of binding sites avail-
able for interactions in trans (Hornberger et al., 1999; Yin
et al., 2004). In contrast, Marquardt et al. (2005) have re-
cently proposed that EphAs and ephrin-As function inde-
pendently from distinct membrane domains. We currently
have no evidence for the compartmentalized distribution of
ephrin-B2 and EphB RTKs in the plasma membrane or
masking by interactions in cis. However, it is also possible
that molecules might interact in trans within the same
cell—for example, at membrane ruffles, in the Golgi appara-
tus, or in endocytic compartments. Irrespective of the exact
mechanism, the striking abnormalities seen in isolated
Dephrin-B2 cells appear more compatible with a role in
cell-autonomous signaling than the masking of EphB recep-
tors. However, the latter may be still relevant in settings in-
volving cell-cell contacts such as interactions between PCs
and ephrin-B2-expressing ECs or between neighboring mu-
ral cells (Figure 7B).
Implications for Ephrin-B2 in Disease
Whereas research over many years has established roles for
Eph/ephrin molecules in a range of developmental pro-
cesses, significantly less is known about pathological condi-
tions. Several of our results hint at a possible involvement of
ephrin-B2 in disease processes. (1) Compromised mural-
cell coverage and vascular integrity in Efnb2DPC/vSMC mice
recapitulate aspects of the pericyte loss in the retinae of
diabetic patients, which leads to the ballooning of capil-
laries (microaneurysms), high vascular permeability, ectopic
sprouting of blood vessels, and blindness (Adamis et al.,
1999; Betsholtz et al., 2005). (2) Tumor blood vessels are fre-
quently disorganized, leaky, and poorly functional. These de-
fects may involve loose association of pericytes (Morikawa
et al., 2002) similar to defects in Efnb2DPC/vSMC mutants.Cell 124, 161–173, January 13, 2006 ª2006 Elsevier Inc. 171
(3) Altered expression of Eph receptors and ephrins has
been also linked to cancer cell invasion and malignancy
(Andres and Ziemiecki, 2003; Brantley-Sieders et al., 2004)
and may affect cancer cell motility, invasion and metastasis.
Future genetic experiments, such as spatially and tempor-
ally controlled gene inactivation, will address the role of
ephrin-B2 in animal models of human diseases without
compromising essential roles during developmental tissue
morphogenesis.
EXPERIMENTAL PROCEDURES
Generation of Mutant Mice
Pdgfrb-Cre transgenic mice were generated by pronuclear injection of
a Pdgfrb gene fragment (S.S.F. and R.H.A., unpublished data) and
a cDNA encoding Cre recombinase followed by an SV40 polyadenylation
signal. Cre activity of transgenic founders was characterized in a ROSA26
Cre reporter background (Soriano, 1999). Pdgfrb-Cre and Efnb2 condi-
tional mice (Grunwald et al., 2004) were bred to generate Efnb2DPC/vSMC
mutants. Cre-negative littermates were used as controls. Animals were
in a mixed 129  C57BL/6 genetic background. See Supplemental
Data for details of breeding, genotyping, and RT-PCR analysis.
Staining of Tissues and Tissue Sections
Freshly isolated embryos or tissues were frozen in liquid nitrogen, embed-
ded in OCT compound, and sectioned (5 mm) with a Bright cryostat. Alter-
natively, samples were fixed overnight in 4% paraformaldehyde at 4ºC or
zinc fixative (0.1 M Tris [pH 7.4], 0.5 g/l calcium acetate, 5 g/l zinc acetate,
5 g/l zinc chloride) at room temperature overnight followed by embedding
and sectioning in paraffin. Selected paraffin sections were stained with
hematoxylin and eosin using standard protocols. See Supplemental
Data for details of antibody stainings.
For b-galactosidase staining, tissues were dissected from E18.5 em-
bryos, fixed in 0.25% glutaraldehyde/PBS (5 min), and stained as previ-
ously described (Compagni et al., 2003).
Electron Microscopy
Skin samples were fixed in 2.5% glutaraldehyde in Sorensen’s phosphate
buffer (pH 7.4), postfixed in osmium tetroxide in the same buffer, and em-
bedded in araldite. Sections were cut on a Reichert Ultracut, stained with
lead citrate and uranyl acetate, and viewed in a JEOL 1010.
SMC Culture
Aortas from adult Efnb2lox/lox homozygotes carrying the ‘‘immorto’’ trans-
gene (Supplemental Data) were isolated and placed in DMEM. After re-
moval of the adventitial layer, aortas were cut longitudinally into 5  5 mm
pieces, placed in six-well dishes (luminal side touching the plastic), and
cultured at 33ºC and 8% CO2 in DMEM containing 10% FCS, 2 mM
L-glutamin, primocin (100 mg/ml, InvivoGen), and 50 U/ml IFNg (Pepro-
Tech). Once a significant number of cells had sprouted out, the aorta
pieces were removed, and the remaining cells were propagated under
the same culture conditions. SMC identity was confirmed by staining
with a-SMA antibody.
See Supplemental Data for information about biochemistry, immuno-
fluorescence, and stimulation experiments.
Video Microscopy
Control or Dephrin-B2 cells were seeded in 35 mm glass-bottom Petri
dishes (MatTek) and recorded at a 5 min lapse interval on inverted Olym-
pus microscopes IM or IMT-2 equipped with 10 NA 0.25 or 4 NA 0.1
phase-contrast objective lenses. The microscopes were enclosed in Per-
spex environmental incubators with 37ºC temperature control, and the
cells on the stage were kept in humidified stainless-steel chambers sup-
plied with 10% CO2. AQM software (Kinetic Imaging) acquired time-lapse
images using XCD-X700 or XCD-X710 cameras (Sony) and operated illu-172 Cell 124, 161–173, January 13, 2006 ª2006 Elsevier Inc.mination shutters to minimize the exposure of the cells to illumination.
Motion-analysis software (Kinetic Imaging) was used to interactively ex-
tract cell trajectories from recorded sequences. Custom-developed
Mathematica software was used to evaluate and statistically test cell
speed using ANOVA.
Interference Reflection Microscopy (IRM)
Time-lapse IRM images of ephrin-B2-deficient or control cells in 35 mm
glass-bottom Petri dishes were acquired at 30 s lapse interval on an in-
verted LSM 510 laser scanning confocal microscope (Carl Zeiss Ltd.)
equipped with a 63 NA 1.4 objective lens, Perspex environmental incu-
bator with 37ºC temperature control, and humidified stainless-steel
chambers supplied with 10% CO2. Reflection imaging was set with 633
nm laser line, 80/20 mirror instead of the main dichroic, and no emission
filter.
Supplemental Data
Supplemental Data includeSupplemental Experimental Procedures, Sup-
plemental References, 6 figures, and 14movies and can be foundwith this
article online at http://www.cell.com/cgi/content/full/124/1/161/DC1/.
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